The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
35 | 80 | 88 | 55 |
|
Growth
|
63 | 77 | 33 | 7 |
|
|
4 | 37 | 28 | 8 |
|
Sentiment
|
14 | 10 | 45 | 1 |
|
|
9 | 47 | 39 | 1 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Analyst Opinions
|
26 | 36 | 57 | 9 |
|
Opinions Change
|
50 | 31 | 50 | 37 |
|
Pro Holdings
|
n/a | 28 | 32 | 53 |
|
Market Pulse
|
36 | 11 | 48 | 20 |
|
Sentiment
|
14 | 10 | 45 | 1 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
35 | 80 | 88 | 55 |
|
Growth
|
63 | 77 | 33 | 7 |
|
Safety
|
4 | 37 | 28 | 8 |
|
Combined
|
9 | 84 | 49 | 4 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Price vs. Sales (P/S)
|
3 | 7 | 100 | 14 |
|
Price vs. Earnings (P/E)
|
54 | 76 | 82 | 38 |
|
Price vs. Book (P/B)
|
92 | 92 | 100 | 92 |
|
Dividend Yield
|
1 | 1 | 1 | 1 |
|
Value
|
35 | 80 | 88 | 55 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Revenue Growth
|
6 | 43 | 98 | 17 |
|
Profit Growth
|
79 | 86 | 51 | 12 |
|
Capital Growth
|
42 | 98 | 1 | 95 |
|
Stock Returns
|
90 | 29 | 11 | 5 |
|
Growth
|
63 | 77 | 33 | 7 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Leverage
|
1 | 25 | 14 | 1 |
|
Refinancing
|
4 | 74 | 73 | 69 |
|
Liquidity
|
45 | 24 | 31 | 23 |
|
Safety
|
4 | 37 | 28 | 8 |
Discover high‑ranked alternatives to Esperion Therapeutics and broaden your portfolio horizons.
USA
USA
USA
The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.
Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.
The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.
Become an Obermatt subscriber and see all of the similar stocks here.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
Top 10 Market ListsSimilar Stocks1 WatchlistDelivered to your inboxTop 10 Market ListsSimilar Stocks
Stock Filters6 key ranks for 6,500+ stocks3 WatchlistsDelivered to your inboxTop 10 Market ListsSimilar StocksStock FiltersInvestment Themes6 key ranks for 6,500+ stocks15 more detailed ranks3 years of historical ranksUnlimited WatchlistsDelivered to your inbox
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.
See how Obermatt improved their investing:
Add to Watchlist
See Similar Stocks
